More vaccines, more protection: Promising results for new typhoid conjugate vaccine Phase 3 results from a trial of a new typhoid conjugate vaccine show positive results, offering the potential for an additional product to increase access.

#Typhoid is a serious public health threat in many parts of the world. We can prevent it with vaccines—but to ensure access, we need more of them.

That's why PATH supported a study of #EuBiologics’ new typhoid vaccine. Results are promising: https://bit.ly/4r8aBKb

#VaccinesWork #TakeOnTyphoid

EuTYPH-C Inj.® Multi-dose demonstrates strong safety and immunogenicity: Results now available from a Phase 3 study

#JustPublished in @lancetgh.bsky.social: results from a Phase 3 clinical trial of #EuBiologics’ typhoid conjugate vaccine. The vaccine demonstrates strong safety & immunogenicity—a crucial step toward a sustainable supply of lifesaving typhoid vaccine. https://bit.ly/47HyvVe

#TakeOnTyphoid

We are pleased to announce the initiation of the new EuNmCV5 Meningitis Vaccine Study, in collaboration with our partners, #EuBiologics & @pathmalaria.bsky.social.

This critical study aims to ensure the safety & effectiveness of the vaccine in preventing meningitis in children.

#GlobalHealth